Publications

Kendre G, Marhenke S, Lorz G, Kühnel F, Woller N, Reineke-Plaaß T, Poth T, Becker D, Marquardt JU, Wirtz RM, Bonin M, Saborowski M, Vogel A*, Saborowski A*. The co-mutational spectrum determines the therapeutic response in murine FGFR2 fusion - driven cholangiocarcinoma. Hepatology 2021; doi: 10.1002/hep.31799. *equal contribution.Buitrago-Molina LE, Marhenke S, Becker D, Geffers R, Itzel T, Teufel A, Jaeschke H, Lechel A, Unger K, Markovic J, Sharma AD, Marquardt JU, Saborowski M, Saborowski A*, Vogel A*. p53-independent induction of p21 fails to control regeneration and hepatocarcinogenesis in a murine liver injury model. Cell Mol Gastroenterol Hepatol 2021; 11:1387-1404. *equal contribution.Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Ji T, Lihou CF, Zhen H, Féliz L, Vogel A. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020;21:671-684.A Vogel, A Cervantes, I Chau, B Daniele, JM Llovet, T Meyer, JC Nault, U Neumann, J Ricke, B Sangro, P Schirmacher, C Verslype, CJ Zech, D Arnold, E Martinelli; ESMO Guidelines Committee. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;29:iv238-iv255.AX Zhu, RS Finn, J Edeline, S Cattan, S Ogasawara, D Palmer, C Verslype, V Zagonel, L Fartoux, A Vogel, D Sarker, G Verset, SL Chan, J Knox, B Daniele, AL Webber, SW Ebbinghaus, J Ma, AB Siegel, AL Cheng, M Kudo. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-952Endig J, Buitrago-Molina LE, Marhenke S, Reisinger F, Saborowski A, Schütt J, Limbourg F, Könecke C, Schreder A, Michael A, Misslitz AC, Healy ME, Geffers R, Clavel T, Unger K, Finegold M, Weber A, Manns MP, Longerich T, Heikenwälder M, Vogel A. Dual role of the adaptive immune system in liver injury and hepatocellular carcinoma development. Cancer Cell 2016;30:308-323Wuestefeld T, Pesic M, Longerich T, Kang TW, Yevsa T, Dauch D, Potapova A, Rittelmeier I, Jarek M, Geffers R, Scharfe M, Klawonn F, Malek NP, Schirmacher P, Ott M, Vogel A, Manns MP, Zender L. A direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. Cell 2013;153:389-401.Buitrago-Molina LE, Marhenke S, Longerich T, Boukouris AE, Geffers R, Guigas B, Manns MP, Vogel A. The degree of liver injury determines the role of p21 in liver regeneration and hepatocarcinogenesis in mice. Hepatology 2013;58:1143-1152.Buitrago-Molina LE, Pothiraju D, Lamlé J, Marhenke S, Kossatz U, Breuhahn K, Manns MP, Malek N, Vogel A. Rapamycin delays tumor development in murine livers by inhibiting proliferation of hepatocytes with DNA damage. Hepatology 2009;50:500-509. Marhenke S, Lamlé J, Buitrago-Molina LE, Cañón JM, Geffers R, Finegold M, Sporn M, Yamamoto M, Manns MP, Grompe M, Vogel A. Activation of nuclear factor E2-related factor 2 in hereditary type 1 and its role in survival and liver tumor development. Hepatology 2008;48:487-496. Lamlé J, Marhenke S, Borlak J, von Wasielewski R, Eriksson CJ, Geffers R, Manns MP, Yamamoto M, Vogel A. Nuclear factor-eythroid 2-related factor 2 prevents alcohol-induced fulminant liver injury. Gastroenterology 2008;134:1159-1168. Willenbring H, Sharma AD, Vogel A, Lee AY, Rothfuss A, Wang Z, Finegold M, Grompe M. Loss of p21 Permits Carcinogenesis from Chronically Damaged Liver and Kidney Epithelial Cells Despite Unchecked Apoptosis. Cancer Cell 2008;14:59-67.